IHE 📈 iShares U.S. Pharmaceuticals - Overview

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US4642888360 • Health

IHE: Prescription Drugs, Over-the-Counter Drugs, Vaccines

The iShares U.S. Pharmaceuticals ETF (NYSE ARCA: IHE) is an investment fund that focuses on the pharmaceuticals sector of the U.S. equity market. It aims to track the performance of its underlying index, which is comprised of pharmaceutical companies that manufacture prescription or over-the-counter drugs, vaccines, and other related products.

The fund's investment strategy involves allocating at least 80% of its assets to the component securities of its underlying index, as well as other investments that have similar economic characteristics. This approach allows the fund to closely mirror the performance of the pharmaceuticals sector, providing investors with targeted exposure to this specific industry.

As a non-diversified fund, the iShares U.S. Pharmaceuticals ETF may invest a significant portion of its assets in a smaller number of securities, which can result in higher volatility compared to a diversified fund. However, this concentrated approach can also provide investors with the potential for higher returns if the pharmaceuticals sector performs well.

The fund is managed by BlackRock, a leading global investment management company, and is listed on the NYSE ARCA exchange under the ticker symbol IHE. For more information about the fund, investors can visit the iShares website at http://www.ishares.com.

The fund is domiciled in the United States, which means it is subject to U.S. regulations and tax laws. This can impact the fund's performance and the tax implications for investors, so it's essential to consult with a financial advisor or tax professional before investing.

Additional Sources for IHE ETF

IHE ETF Overview

Market Cap in USD 629m
Category Health
TER 0.40%
IPO / Inception 2006-05-01

IHE ETF Ratings

Growth 5y 62.6%
Fundamental -
Dividend 45.4%
Rel. Performance Sector -1.2
Analysts -
Fair Price Momentum 65.88 USD
Fair Price DCF -

IHE Dividends

Dividend Yield 12m 1.54%
Yield on Cost 5y 2.26%
Annual Growth 5y 2.81%
Payout Consistency 91.93%

IHE Growth Ratios

Growth Correlation 3m -75.4%
Growth Correlation 12m 81%
Growth Correlation 5y 78.7%
CAGR 5y 7.94%
CAGR/Mean DD 5y 1.49
Sharpe Ratio 12m 1.03
Alpha -6.38
Beta 0.66
Volatility 13.72%
Current Volume 33.7k
Average Volume 20d 46.2k
What is the price of IHE stocks?
As of December 04, 2024, the stock is trading at USD 68.93 with a total of 33,705 shares traded.
Over the past week, the price has changed by +0.19%, over one month by +0.86%, over three months by -4.29% and over the past year by +17.44%.
Is iShares U.S. Pharmaceuticals a good stock to buy?
Yes. Based on ValueRay Analyses, iShares U.S. Pharmaceuticals (NYSE ARCA:IHE) is currently (December 2024) a good stock to buy. It has a ValueRay Growth Rating of 62.55 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IHE as of December 2024 is 65.88. This means that IHE is currently overvalued and has a potential downside of -4.42%.
Is IHE a buy, sell or hold?
iShares U.S. Pharmaceuticals has no consensus analysts rating.
What are the forecast for IHE stock price target?
According to ValueRays Forecast Model, IHE iShares U.S. Pharmaceuticals will be worth about 72.5 in December 2025. The stock is currently trading at 68.93. This means that the stock has a potential upside of +5.15%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 72.5 5.2%